Cas:298705-59-6 1-[(2-bromophenyl)methyl]piperazine manufacturer & supplier

We serve Chemical Name:1-[(2-bromophenyl)methyl]piperazine CAS:298705-59-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-[(2-bromophenyl)methyl]piperazine

Chemical Name:1-[(2-bromophenyl)methyl]piperazine
CAS.NO:298705-59-6
Synonyms:1-[(2-bromophenyl)methyl]piperazine
Molecular Formula:C11H15BrN2
Molecular Weight:255.15400
HS Code:2933599090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:325.2ºC at 760 mmHg
Density:1.356g/cm3
Index of Refraction:1.575
PSA:15.27000
Exact Mass:254.04200
LogP:2.12100

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1-[(2-bromophenyl)methyl]piperazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-[(2-bromophenyl)methyl]piperazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-[(2-bromophenyl)methyl]piperazine Use and application,1-[(2-bromophenyl)methyl]piperazine technical grade,usp/ep/jp grade.


Related News: The analysis examined disease manifestations in the two most commonly impacted organ domains in SLE. Anifrolumab is a potential first-in-class type I interferon inhibitor. 2-(3-Diethylamino-propylamino)-N-(1,5-dimethyl-hexyl)-N-(3-methyl-butyl)-acetamide manufacturers A new post-hoc analysis of pooled data from the TULIP phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). 2-[amino-(4-cyano-phenyl)-(3-methyl-3H-imidazol-4-yl)-methyl]-7-pyridin-3-yl-benzofuran-5-carbonitrile suppliers By integrating biocatalysis into ongoing and newly launched projects, Wavelength Pharmaceuticals has shown that it is possible to reduce overall costs by as much as 30%. [(4-nitropyridine)B8H11NHMe] vendor & factory.